\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\\.\ \(14\)\
\-\ unknown\\.\ \(36\)\
\-\ there\\ are\\ multiple\\ area\\ of\\ hypoattenuation\\ and\\ filling\\ defect\\ within\\ the\\ right\\ and\\ left\\ pulmonary\\ arteries\\.\\ \\ there\\ is\\ a\\ comet\\ shaped\\ area\\ of\\ hypoattenuation\\ extending\\ from\\ the\\ left\\ pulmonary\\ artery\\ nearly\\ to\\ the\\ branch\\ point\\ of\\ the\\ main\\ pulmonry\\ artery\\.\ \(0\)\
\-\ pulomary\\ embolism\ \(0\)\
\-\ pulmonary\\ embolism\ \(77\)\
\-\ venous\\ thromboembolism\ \(8\)\
\-\ primary\\ thrombus\ \(1\)\
\-\ septic\\ emboli\ \(22\)\
\-\ tumor\\ emboli\ \(4\)\
\-\ 61\\ years\\-old\\ man\\ with\\ known\\ stage\\ ii\\ pancreatic\\ cancer\\.\\ \\ underwent\\ contrast\\ ct\\ of\\ the\\ chest\\,\\ abdomen\\ and\\ pelvis\\ for\\ pre\\-operative\\ evaluation\\.\ \(0\)\
\-\ venous\\ thromboembolic\\ disease\\,\\ especially\\ resulting\\ in\\ pulmonary\\ embolism\\ represents\\ a\\ significant\\ disease\\ burden\\ in\\ terms\\ of\\ morbidity\\ and\\ mortality\\ in\\ hospitalized\\ and\\ non\\-hospitalized\\ patients1\\.\\ \\ thrombus\\,\\ or\\ clot\\,\\ often\\ forms\\ in\\ the\\ proximal\\,\\ deep\\ leg\\ veins\\ and\\ only\\ may\\ only\\ become\\ clinically\\ evident\\ once\\ a\\ thrombus\\ segment\\ has\\ embolized\\[1\\,\\ 2\\]\\.\\ \\ upon\\ embolization\\ from\\ a\\ vein\\ \\(in\\ the\\ proximal\\ leg\\ or\\ elsewhere\\)\\ the\\ first\\ bed\\ of\\ vessels\\ of\\ decreasing\\ diameter\\ is\\ usually\\ the\\ lungs\\,\\ where\\ the\\ embolus\\ may\\ lodge\\ occluding\\ blood\\ flow\\ and\\ creating\\ clinically\\ significant\\ or\\ insignificant\\ \\(based\\ on\\ size\\)\\ ventilation\\-perfusion\\ mismatches\\[1\\,\\ 3\\]\\.\\ \\ the\\ progression\\ from\\ thrombus\\ formation\\ in\\ the\\ legs\\ to\\ pulmonary\\ embolism\\ is\\ believed\\ to\\ account\\ for\\ up\\ to\\ 10\\%\\ of\\ hospital\\ deaths\\[1\\]\\.\\ \\ tragically\\,\\ acute\\ pulmonary\\ embolism\\ is\\ among\\ the\\ leading\\ causes\\ of\\ preventable\\ hospital\\ deaths\\ in\\ the\\ united\\ states\\[4\\]\\.\ \(0\)\
\-\ \\	detection\\ and\\ therapy\\ for\\ acute\\ pulmonary\\ embolism\\,\\ once\\ it\\ has\\ become\\ clinically\\ apparent\\ is\\ difficult\\ and\\ often\\ without\\ optimum\\ result\\.\\ \\ the\\ best\\ method\\ of\\ preventing\\ pulmonary\\ embolism\\ is\\ to\\ prevent\\ primary\\ thrombus\\ formation\\[1\\,\\ 4\\]\\.\\ \\ extensive\\ clinical\\ trials\\ have\\ resulted\\ in\\ revised\\ clinical\\ guidelines\\ in\\ 2007\\ for\\ the\\ prevention\\ and\\ management\\ of\\ venous\\ thrombosis\\ and\\ venous\\ thromboembolic\\ disease\\[2\\,\\ 5\\]\\.\\ \\ these\\ new\\ recommendations\\ state\\ that\\ \\(1\\)\\ low\\ molecular\\ weight\\ heparins\\ are\\ preferable\\ to\\ unfractionated\\ heparins\\ in\\ inpatient\\ populations\\;\\ \\(2\\)\\ low\\ molecular\\ weight\\ heparins\\ are\\ safe\\ and\\ cost\\ effective\\ for\\ treating\\ deep\\ venous\\ thrombosis\\ and\\ pulmonary\\ embolism\\ in\\ selected\\ outpatients\\;\\ \\(3\\)\\ compression\\ stocking\\ should\\ be\\ utilized\\ to\\ prevent\\ postthrombotic\\ syndrome\\ within\\ one\\ month\\ of\\ diagnosis\\ and\\ used\\ for\\ a\\ minimum\\ of\\ one\\ year\\;\\ \\(4\\)\\ there\\ is\\ inadequate\\ evidence\\ to\\ recommend\\ specific\\ types\\ of\\ anticoagulation\\ in\\ pregnant\\ women\\;\\ \\(5\\)\\ recommendations\\ on\\ length\\ of\\ treatment\\;\\ and\\ \\(6\\)\\ low\\ molecular\\ weight\\ heparin\\ is\\ safe\\ and\\ efficacious\\ for\\ long\\ term\\ treatment\\ on\\ venous\\ thromboembolism\\ in\\ selected\\ patients\\,\\ such\\ as\\ those\\ with\\ cancer\\[2\\,\\ 5\\]\\.\\ \\ for\\ additional\\ information\\ on\\ this\\ complex\\ and\\ everchanging\\ topic\\,\\ the\\ reader\\ is\\ directed\\ to\\ the\\ references\\ below\\ and\\ the\\ references\\â\\€\\™\\ references\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ embolism\\:\\ 0\\.07131410551363518\ \(0\)\
\-\ \\]\\:\\ 0\\.0667419851061614\ \(0\)\
\-\ \\[\\:\\ 0\\.0665493969742822\ \(0\)\
\-\ heparins\\:\\ 0\\.05638924365010553\ \(0\)\
\-\ pulmonary\\:\\ 0\\.04790821490827414\ \(0\)\
\-\ thrombus\\:\\ 0\\.046009688205077115\ \(0\)\
\-\ molecular\\:\\ 0\\.04166055435590055\ \(0\)\
\-\ venous\\:\\ 0\\.03968169234699952\ \(0\)\
\-\ deaths\\:\\ 0\\.029952063772871823\ \(0\)\
\-\ thromboembolism\\:\\ 0\\.028223001478167496\ \(0\)\
\-\ hypoattenuation\\:\\ 0\\.0277737029039337\ \(0\)\
\-\ thromboembolic\\:\\ 0\\.02633885328081552\ \(0\)\
\-\ safe\\:\\ 0\\.026044640609229373\ \(0\)\
\-\ recommendations\\:\\ 0\\.02422185163342153\ \(0\)\
\-\ clinically\\:\\ 0\\.02396554939283326\ \(0\)\
\-\ references\\:\\ 0\\.022725980181630783\ \(0\)\
\-\ selected\\:\\ 0\\.022080734602303254\ \(0\)\
\-\ 1\\:\\ 0\\.021677253389762334\ \(0\)\
\-\ \\;\\:\\ 0\\.02159297642273554\ \(0\)\
\-\ emboli\\:\\ 0\\.019726497577569606\ \(0\)\
\-\ weight\\:\\ 0\\.019592403742905322\ \(0\)\
\-\ pulmonry\\:\\ 0\\.018796414550035178\ \(0\)\
\-\ non\\-hospitalized\\:\\ 0\\.018796414550035178\ \(0\)\
\-\ patients1\\:\\ 0\\.018796414550035178\ \(0\)\
\-\ tragically\\:\\ 0\\.018796414550035178\ \(0\)\
\-\ stocking\\:\\ 0\\.018796414550035178\ \(0\)\
\-\ efficacious\\:\\ 0\\.018796414550035178\ \(0\)\
\-\ everchanging\\:\\ 0\\.018796414550035178\ \(0\)\
\-\ once\\:\\ 0\\.0186476211832673\ \(0\)\
\-\ prevent\\:\\ 0\\.018084466718392818\ \(0\)\
\-\ become\\:\\ 0\\.017358576953531976\ \(0\)\
\-\ years\\-old\\:\\ 0\\.017318488791911626\ \(0\)\
\-\ lodge\\:\\ 0\\.017318488791911626\ \(0\)\
\-\ ventilation\\-perfusion\\:\\ 0\\.017318488791911626\ \(0\)\
\-\ mismatches\\:\\ 0\\.017318488791911626\ \(0\)\
\-\ optimum\\:\\ 0\\.017318488791911626\ \(0\)\
\-\ outpatients\\:\\ 0\\.017318488791911626\ \(0\)\
\-\ postthrombotic\\:\\ 0\\.017318488791911626\ \(0\)\
\-\ reader\\:\\ 0\\.017318488791911626\ \(0\)\
\-\ preventable\\:\\ 0\\.016453957644559463\ \(0\)\
\-\ 5\\:\\ 0\\.015992497371711066\ \(0\)\
\-\ pulomary\\:\\ 0\\.015840563033788075\ \(0\)\
\-\ unfractionated\\:\\ 0\\.015840563033788075\ \(0\)\
\-\ 2\\:\\ 0\\.01569385498090018\ \(0\)\
\-\ thrombosis\\:\\ 0\\.01564189316483175\ \(0\)\
\-\ occluding\\:\\ 0\\.0153647772100904\ \(0\)\
\-\ preferable\\:\\ 0\\.0153647772100904\ \(0\)\
\-\ 4\\:\\ 0\\.015230097474492827\ \(0\)\
\-\ low\\:\\ 0\\.015199369208100636\ \(0\)\
\-\ formation\\:\\ 0\\.01504158376661818\ \(0\)\
\-\ minimum\\:\\ 0\\.014976031886435912\ \(0\)\
\-\ deep\\:\\ 0\\.014750243707012731\ \(0\)\
\-\ insignificant\\:\\ 0\\.014647352398531311\ \(0\)\
\-\ revised\\:\\ 0\\.014647352398531311\ \(0\)\
\-\ comet\\:\\ 0\\.014362637275664525\ \(0\)\
\-\ leg\\:\\ 0\\.014329199610272054\ \(0\)\
\-\ cost\\:\\ 0\\.01388685145196685\ \(0\)\
\-\ hospital\\:\\ 0\\.013718961471079417\ \(0\)\
\-\ populations\\:\\ 0\\.013498106128312362\ \(0\)\
\-\ trials\\:\\ 0\\.01316942664040776\ \(0\)\
\-\ burden\\:\\ 0\\.013022320304614686\ \(0\)\
\-\ prevention\\:\\ 0\\.013022320304614686\ \(0\)\
\-\ guidelines\\:\\ 0\\.012755447931578427\ \(0\)\
\-\ hospitalized\\:\\ 0\\.012518293059275177\ \(0\)\
\-\ elsewhere\\:\\ 0\\.012518293059275177\ \(0\)\
\-\ for\\:\\ 0\\.012436812770024992\ \(0\)\
\-\ creating\\:\\ 0\\.012408925693843298\ \(0\)\
\-\ preventing\\:\\ 0\\.012408925693843298\ \(0\)\
\-\ \\(\\:\\ 0\\.01232173520245391\ \(0\)\
\-\ \\)\\:\\ 0\\.01217121862879838\ \(0\)\
\-\ embolized\\:\\ 0\\.012110925816710765\ \(0\)\
\-\ inadequate\\:\\ 0\\.012110925816710765\ \(0\)\
\-\ recommend\\:\\ 0\\.012110925816710765\ \(0\)\
\-\ cancer\\:\\ 0\\.011979382790468082\ \(0\)\
\-\ pre\\-operative\\:\\ 0\\.011933139870145623\ \(0\)\
\-\ terms\\:\\ 0\\.011769043833608037\ \(0\)\
\-\ in\\:\\ 0\\.011680520238429241\ \(0\)\
\-\ often\\:\\ 0\\.011626752872152035\ \(0\)\
\-\ decreasing\\:\\ 0\\.011616679304861457\ \(0\)\
\-\ utilized\\:\\ 0\\.011544394546491135\ \(0\)\
\-\ area\\:\\ 0\\.011521689740444636\ \(0\)\
\-\ method\\:\\ 0\\.011341174546908353\ \(0\)\
\-\ treating\\:\\ 0\\.011277522173454875\ \(0\)\
\-\ united\\:\\ 0\\.011215715058586534\ \(0\)\
\-\ heparin\\:\\ 0\\.011215715058586534\ \(0\)\
\-\ clinical\\:\\ 0\\.011212408529066116\ \(0\)\
\-\ morbidity\\:\\ 0\\.011097229235228727\ \(0\)\
\-\ embolus\\:\\ 0\\.010984982468735293\ \(0\)\
\-\ inpatient\\:\\ 0\\.010984982468735293\ \(0\)\
\-\ only\\:\\ 0\\.010956979353880321\ \(0\)\
\-\ proximal\\:\\ 0\\.010940482651202623\ \(0\)\
\-\ believed\\:\\ 0\\.010930999935719747\ \(0\)\
\-\ directed\\:\\ 0\\.010878350441923647\ \(0\)\
\-\ artery\\:\\ 0\\.010850874166772703\ \(0\)\
\-\ among\\:\\ 0\\.010826969734932046\ \(0\)\
\-\ primary\\:\\ 0\\.010794815620024292\ \(0\)\
\-\ is\\:\\ 0\\.010790228156636527\ \(0\)\
\-\ 61\\:\\ 0\\.010727779936136965\ \(0\)\
\-\ pregnant\\:\\ 0\\.010727779936136965\ \(0\)\
\-\ clot\\:\\ 0\\.010633000058587213\ \(0\)\
\-\ forms\\:\\ 0\\.010587144610354883\ \(0\)\
\-\ bed\\:\\ 0\\.010587144610354883\ \(0\)\
\-\ detection\\:\\ 0\\.010587144610354883\ \(0\)\
\-\ effective\\:\\ 0\\.010371587857963903\ \(0\)\
\-\ account\\:\\ 0\\.010291118075484485\ \(0\)\
\-\ resulted\\:\\ 0\\.010291118075484485\ \(0\)\
\-\ 2007\\:\\ 0\\.010291118075484485\ \(0\)\
\-\ state\\:\\ 0\\.010291118075484485\ \(0\)\
\-\ nearly\\:\\ 0\\.0100312250741859\ \(0\)\
\-\ mortality\\:\\ 0\\.009928860001293872\ \(0\)\
\-\ information\\:\\ 0\\.009928860001293872\ \(0\)\
\-\ one\\:\\ 0\\.009875187135653066\ \(0\)\
\-\ branch\\:\\ 0\\.009863248788784803\ \(0\)\
\-\ legs\\:\\ 0\\.009863248788784803\ \(0\)\
\-\ significant\\:\\ 0\\.009798921752896475\ \(0\)\
\-\ topic\\:\\ 0\\.009677723464713097\ \(0\)\
\-\ septic\\:\\ 0\\.009562441543028075\ \(0\)\
\-\ types\\:\\ 0\\.009298872340539424\ \(0\)\
\-\ shaped\\:\\ 0\\.009274222399385745\ \(0\)\
\-\ anticoagulation\\:\\ 0\\.009201937641015423\ \(0\)\
\-\ length\\:\\ 0\\.009132023306638043\ \(0\)\
\-\ progression\\:\\ 0\\.00906432885394171\ \(0\)\
\-\ acute\\:\\ 0\\.008997353215805949\ \(0\)\
\-\ disease\\:\\ 0\\.008934355274300879\ \(0\)\
\-\ pancreatic\\:\\ 0\\.008914263189204397\ \(0\)\
\-\ women\\:\\ 0\\.008853047611629918\ \(0\)\
\-\ represents\\:\\ 0\\.008754772329753016\ \(0\)\
\-\ veins\\:\\ 0\\.008716696386469418\ \(0\)\
\-\ leading\\:\\ 0\\.008716696386469418\ \(0\)\
\-\ \\,\\:\\ 0\\.008658104440851409\ \(0\)\
\-\ states\\:\\ 0\\.008570848354732957\ \(0\)\
\-\ 3\\:\\ 0\\.00853294467678695\ \(0\)\
\-\ main\\:\\ 0\\.008484512829456333\ \(0\)\
\-\ embolization\\:\\ 0\\.008484512829456333\ \(0\)\
\-\ evident\\:\\ 0\\.00833740649366326\ \(0\)\
\-\ term\\:\\ 0\\.00833740649366326\ \(0\)\
\-\ those\\:\\ 0\\.0082905431531115\ \(0\)\
\-\ to\\:\\ 0\\.008195336835792913\ \(0\)\
\-\ there\\:\\ 0\\.008134641086129992\ \(0\)\
\-\ from\\:\\ 0\\.008100868101199652\ \(0\)\
\-\ apparent\\:\\ 0\\.008056643542756651\ \(0\)\
\-\ resulting\\:\\ 0\\.008001968850617337\ \(0\)\
\-\ may\\:\\ 0\\.007992871509160443\ \(0\)\
\-\ difficult\\:\\ 0\\.007975148419472647\ \(0\)\
\-\ point\\:\\ 0\\.007961863665206898\ \(0\)\
\-\ segment\\:\\ 0\\.007948661170008772\ \(0\)\
\-\ below\\:\\ 0\\.007909537206963576\ \(0\)\
\-\ ii\\:\\ 0\\.007858464198386834\ \(0\)\
\-\ stage\\:\\ 0\\.007771928419889864\ \(0\)\
\-\ diameter\\:\\ 0\\.007665591895283951\ \(0\)\
\-\ best\\:\\ 0\\.007665591895283951\ \(0\)\
\-\ arteries\\:\\ 0\\.007542438730780344\ \(0\)\
\-\ specific\\:\\ 0\\.007531587836308123\ \(0\)\
\-\ especially\\:\\ 0\\.007499362595774971\ \(0\)\
\-\ are\\:\\ 0\\.007451218800829009\ \(0\)\
\-\ upon\\:\\ 0\\.0074467131019788696\ \(0\)\
\-\ where\\:\\ 0\\.007436337431080847\ \(0\)\
\-\ treatment\\:\\ 0\\.007375765286144508\ \(0\)\
\-\ filling\\:\\ 0\\.007335266559237384\ \(0\)\
\-\ vessels\\:\\ 0\\.007335266559237384\ \(0\)\
\-\ additional\\:\\ 0\\.007305856490724941\ \(0\)\
\-\ complex\\:\\ 0\\.00729614259619219\ \(0\)\
\-\ extensive\\:\\ 0\\.007286472755754255\ \(0\)\
\-\ unknown\\:\\ 0\\.007110617272120483\ \(0\)\
\-\ causes\\:\\ 0\\.007092922596609407\ \(0\)\
\-\ result\\:\\ 0\\.006989731677927423\ \(0\)\
\-\ used\\:\\ 0\\.006989731677927423\ \(0\)\
\-\ within\\:\\ 0\\.006951519865185849\ \(0\)\
\-\ based\\:\\ 0\\.006948167083724862\ \(0\)\
\-\ and\\:\\ 0\\.006908661200810091\ \(0\)\
\-\ lungs\\:\\ 0\\.00689933602980869\ \(0\)\
\-\ management\\:\\ 0\\.006875333568135696\ \(0\)\
\-\ has\\:\\ 0\\.0068430702366493725\ \(0\)\
\-\ defect\\:\\ 0\\.006820356772494513\ \(0\)\
\-\ compression\\:\\ 0\\.006820356772494513\ \(0\)\
\-\ pelvis\\:\\ 0\\.006620663979939507\ \(0\)\
\-\ vein\\:\\ 0\\.006592608362503448\ \(0\)\
\-\ or\\:\\ 0\\.006406328884629259\ \(0\)\
\-\ new\\:\\ 0\\.006349228095523579\ \(0\)\
\-\ long\\:\\ 0\\.006281922197937577\ \(0\)\
\-\ underwent\\:\\ 0\\.006252017133215819\ \(0\)\
\-\ on\\:\\ 0\\.006173910553223267\ \(0\)\
\-\ 10\\:\\ 0\\.006142055923980619\ \(0\)\
\-\ available\\:\\ 0\\.00612520053057526\ \(0\)\
\-\ extending\\:\\ 0\\.00612520053057526\ \(0\)\
\-\ first\\:\\ 0\\.00611403717438348\ \(0\)\
\-\ size\\:\\ 0\\.0061084773376946086\ \(0\)\
\-\ flow\\:\\ 0\\.00602143683765142\ \(0\)\
\-\ should\\:\\ 0\\.005808546997630703\ \(0\)\
\-\ known\\:\\ 0\\.005765567344272537\ \(0\)\
\-\ such\\:\\ 0\\.005695805522048725\ \(0\)\
\-\ the\\:\\ 0\\.005600717290765224\ \(0\)\
\-\ usually\\:\\ 0\\.005532896063681789\ \(0\)\
\-\ month\\:\\ 0\\.005466129084862706\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.005445686012037219\ \(0\)\
\-\ 6\\:\\ 0\\.0054416208131660435\ \(0\)\
\-\ abdomen\\:\\ 0\\.005397407810012146\ \(0\)\
\-\ evaluation\\:\\ 0\\.005292620033745859\ \(0\)\
\-\ syndrome\\:\\ 0\\.0052108882233148\ \(0\)\
\-\ blood\\:\\ 0\\.004973157937120041\ \(0\)\
\-\ up\\:\\ 0\\.004899460876448237\ \(0\)\
\-\ therapy\\:\\ 0\\.004871302337400027\ \(0\)\
\-\ evidence\\:\\ 0\\.004777063077541317\ \(0\)\
\-\ these\\:\\ 0\\.004741673117180895\ \(0\)\
\-\ patients\\:\\ 0\\.004715510872848669\ \(0\)\
\-\ chest\\:\\ 0\\.004359763326348654\ \(0\)\
\-\ man\\:\\ 0\\.004309023119594881\ \(0\)\
\-\ without\\:\\ 0\\.0042900067512967165\ \(0\)\
\-\ \\%\\:\\ 0\\.004250151457027735\ \(0\)\
\-\ tumor\\:\\ 0\\.00424783006740045\ \(0\)\
\-\ a\\:\\ 0\\.00422814287653093\ \(0\)\
\-\ diagnosis\\:\\ 0\\.004183836526184264\ \(0\)\
\-\ it\\:\\ 0\\.004095625553375302\ \(0\)\
\-\ contrast\\:\\ 0\\.004078412978268455\ \(0\)\
\-\ left\\:\\ 0\\.004077207971313069\ \(0\)\
\-\ have\\:\\ 0\\.0039454969687955045\ \(0\)\
\-\ multiple\\:\\ 0\\.0038375394530474815\ \(0\)\
\-\ of\\:\\ 0\\.003726134353880227\ \(0\)\
\-\ that\\:\\ 0\\.0031470804446883226\ \(0\)\
\-\ be\\:\\ 0\\.002809715828025435\ \(0\)\
\-\ as\\:\\ 0\\.002756028797215624\ \(0\)\
\-\ not\\:\\ 0\\.002632875632712016\ \(0\)\
\-\ ct\\:\\ 0\\.002548621862243162\ \(0\)\
\-\ this\\:\\ 0\\.002049333077428855\ \(0\)\
\-\ year\\:\\ 0\\.0020386039856565346\ \(0\)\
\-\ right\\:\\ 0\\.0019224556697450248\ \(0\)\
\-\ \\.\\:\\ 0\\.0012110715939393185\ \(0\)\
\-\ with\\:\\ 0\\.0004989517104046471\ \(0\)\
